Olema Pharmaceuticals Inc Share
Olema Pharmaceuticals Inc Share price
Key metrics
| Market capitalization | $623.10m |
| Enterprise Value | $376.33m |
| PER (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 2.63 |
| Turnover (TTM) Turnover | $0.00 |
| EBIT (operating result TTM) EBIT | $-109.70m |
| Free cash flow (TTM) Free cash flow | $-86.99m |
| Cash position | $248.98m |
Is Olema Pharmaceuticals Inc a top scorer stock according to the dividend, high growth investing or Leverman strategy?
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
Olema Pharmaceuticals Inc Share analysis
Analyst opinions
9 Analysts have issued a Olema Pharmaceuticals Inc forecast:
Analyst opinions
9 Analysts have issued a Olema Pharmaceuticals Inc forecast:
Financial data from Olema Pharmaceuticals Inc
| Dec '23 |
+/-
%
|
||
| Net profit | -97 -97 |
8%
8%
|
|
| Depreciation and amortization | 0.38 0.38 |
77%
77%
|
|
| Share compensation | 17 17 |
8%
8%
|
|
| Operating cash flow | -84 -84 |
2%
2%
|
|
| Investments | - - |
-
|
|
| Dividend paid | - - |
-
|
|
| Free cash flow | -84 -84 |
2%
2%
|
|
Figures in millions USD.
Don't miss a thing! We will send you all news about the Olema Pharmaceuticals Inc share directly to your mailbox free of charge.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Olema Pharmaceuticals Inc Share News
Company profile
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
| Head office | United States |
| CEO | Sean Bohen |
| Employees | 74 |
| Founded | 2006 |
| Website | www.olema.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
